Quick Facts

• Daliresp is approved for use in adults with severe Chronic Obstructive Pulmonary Disease (COPD).
• Its established therapeutic purpose is to help reduce the occurrence of COPD exacerbations (flare-ups).
• The medication is utilized for individuals with severe COPD associated with chronic bronchitis and a history of previous exacerbations.

---

What Daliresp Treats: Main Uses and Benefits

Daliresp is a prescription medication indicated for the management of severe Chronic Obstructive Pulmonary Disease (COPD) in adult patients. Its primary use is a treatment to reduce the risk of future COPD exacerbations, which are periods when symptoms worsen substantially and may necessitate more intensive medical care.

The medication is generally intended for individuals who have severe COPD linked to chronic bronchitis and who have a documented history of experiencing these acute worsening events. Reducing the frequency of exacerbations supports the maintenance of respiratory function and assists in minimizing periods of significant symptom intensification.

It is important to understand that Daliresp is a maintenance treatment and is not intended for the immediate relief of sudden breathing difficulties or acute bronchospasm.

Who Can and Cannot Use Daliresp?

This medication is officially approved for use only in adults diagnosed with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of exacerbations. Its use is limited to maintenance treatment and must not be used for the immediate relief of acute bronchospasm or sudden breathing problems, as it is not a rescue inhaler.

---

Official Eligibility Restrictions

Category	Regulatory Status
Age Group	Adults only; efficacy and safety are not established in the pediatric population (under 18 years).
Hepatic Function	Use is contraindicated in patients with moderate or severe liver impairment (Child-Pugh B or C). Caution is required for mild impairment.
Pregnancy/Lactation	Not recommended during pregnancy; should not be used while breastfeeding, as a risk to the infant cannot be excluded.
Contraindication	Patients with known hypersensitivity to roflumilast or any of the excipients are absolutely prohibited from use.

---

Patients with a history of depression or suicidal behavior require careful evaluation before use. No dose adjustment is generally necessary for patients with renal impairment.

Interactions with other medicines and products

Daliresp (roflumilast) metabolism is primarily dependent on the cytochrome P450 enzymes CYP3A4 and CYP1A2. The concurrent use of other medicines that affect these enzymes may alter the concentration of Daliresp in the body, which can impact its effectiveness or increase the risk of side effects.

Documented Interaction Categories

Interaction Type	Interacting Products (Examples)	Severity/Restriction
Strong CYP450 Inducers	Rifampicin, phenobarbital, carbamazepine, phenytoin	Not Recommended (May decrease effectiveness)
CYP3A4/CYP1A2 Inhibitors	Erythromycin, ketoconazole, fluvoxamine, cimetidine	Use With Caution (May increase side effects)
Oral Contraceptives	Gestodene and ethinyl estradiol combination	Use With Caution (May increase side effects)

Co-administration with strong CYP450 enzyme inducers is generally not recommended because they can substantially reduce the body's exposure to Daliresp and its active form, potentially reducing the therapeutic benefit. Conversely, medicines classified as CYP3A4 inhibitors or dual CYP3A4/CYP1A2 inhibitors can increase systemic exposure to Daliresp, leading to a higher potential for dose-related adverse reactions. The risk of concurrent use with these inhibitors or with oral contraceptives containing gestodene and ethinyl estradiol must be weighed carefully against the clinical benefit. No clinically significant interactions have been observed when Daliresp is co-administered with commonly used treatments like salbutamol, formoterol, budesonide, or theophylline.

Selective Inhibition of the PDE4 Enzyme

Roflumilast's action begins with the selective inhibition of the Phosphodiesterase 4 (PDE4) enzyme, exhibiting high affinity for this enzyme class. This enzyme is responsible for breaking down the cellular messenger cyclic AMP (cAMP). By blocking PDE4, the drug prevents the degradation of cAMP, which initiates a specific anti-inflammatory signaling cascade within immune cells.

---

Upregulation of Anti-inflammatory Signaling

The resulting sustained increase in intracellular cAMP levels activates Protein Kinase A (PKA). This cAMP/PKA pathway modulation influences the function of key immune cells (e.g., neutrophils and monocytes), leading to a reduction in the production and release of pro-inflammatory mediators like cytokines and chemokines.

---

Modulation of Chronic Inflammatory Activity

This molecular cascade results in a physiological effect characterized by the modulation of chronic inflammatory activity in the respiratory system. By modulating the signaling driven by inflammatory mediators, the mechanism influences downstream processes, including airway smooth muscle tone and mucus hypersecretion, resulting in long-term physiological changes.

Official Dosing and Administration Guidelines

Daliresp (Roflumilast) is an oral tablet prescribed as a once-daily maintenance therapy. The medication is not a bronchodilator and is explicitly not intended for the immediate relief of acute breathing difficulties or bronchospasm, serving solely as a continuous treatment.

Standard Regimen and Dosage

The established maintenance dose for adults is one 500 mcg tablet taken once daily. To potentially reduce treatment discontinuation rates, an initial four-week titration period is permitted, where the patient takes one 250 mcg tablet once daily. It is crucial to note that the 250 mcg strength is considered a sub-therapeutic starting dose and must not be used for long-term maintenance.

Administration is straightforward: the tablet should be swallowed whole with water and may be taken with or without food. For consistent use, it is often recommended to take the tablet at the same time each day.

Dosing for Specific Populations

For older adults (age 65 and above) and patients with renal impairment (kidney problems), no adjustment to the standard dose is required. However, use must be approached with caution in patients with mild hepatic impairment (Child-Pugh A), and the medication is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C). If a dose is missed, patients should take the next scheduled dose at the usual time and should not double the dose to compensate.

Recent Clinical Evidence for Daliresp (Roflumilast)

Combination Therapy Research

Research has explored whether adding Daliresp (Roflumilast) to standard bronchodilator therapy may influence the rate of Chronic Obstructive Pulmonary Disease (COPD) exacerbations. Studies primarily focused on participants with severe COPD and a history of frequent exacerbations, who had previously been treated with bronchodilator monotherapy.

Key Phase 3 trials examined whether the addition of Daliresp was associated with a lower annual rate of moderate-to-severe COPD exacerbations, finding that the measured change was statistically significant compared to those receiving standard therapy alone. This difference was consistent in reducing the need for oral corticosteroids.

Safety and Tolerability Profile

Long-term studies monitored the tolerability of Daliresp, reporting that most participants tolerated the treatment well. The most commonly reported events included diarrhea, nausea, and weight loss, which were generally mild to moderate in severity.

Trial protocols excluded participants with severe liver impairment, and the prescribing information notes that Daliresp is not indicated for the relief of acute bronchospasm.

Scope and Duration

Studies have evaluated the addition of Daliresp across different patient presentations of severe COPD, with treatment duration in pivotal trials extending up to one year. Data analysis showed a consistent pattern of effect on exacerbation rates throughout the study periods. Further research is needed to clarify the long-term impact beyond one year of use in this patient population.

Key Studies & References

1. Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS: The REACT Trial (NCT01329029)
2. Roflumilast: a review of its use in the treatment of COPD (Systematic Review)

Common questions about Daliresp (FAQ)

Q: How is Daliresp different from standard inhalers used for COPD?

Daliresp is an oral tablet that belongs to a class of medicines called selective PDE4 inhibitors. Its action is thought to work systemically by influencing chronic inflammation, unlike many inhaled medications that primarily open airways. Official regulatory information states that Daliresp is not a bronchodilator and is specifically not indicated for the immediate relief of sudden breathing problems.

Q: Why does Daliresp sometimes cause changes in mood or sleep?

Regulatory documents list psychiatric effects, including insomnia, anxiety, and depression, among the documented adverse reactions. While the precise physiological reason for these mood and sleep changes is not detailed in patient-facing drug labels, they are categorized in official documentation as warnings.

Q: What are the signs of a serious or unusual allergic reaction to Daliresp?

Official safety information documents the potential for rare but serious hypersensitivity reactions, such as Angioedema. Official safety information advises patients to seek medical attention if symptoms such as swelling of the face, lips, tongue, or throat occur, as these can indicate a serious hypersensitivity reaction like Angioedema.

Q: What are the reasons someone might need to stop taking Daliresp?

Official prescribing information notes that treatment discontinuation may be considered in cases of unexplained or clinically significant weight loss, or if a patient experiences serious psychiatric events like suicidal thoughts or behavior. The medicine's use is formally contraindicated in patients with moderate or severe liver impairment.

Q: Is it true that taking certain antibiotics could interact with Daliresp?

Yes, official product information describes that Daliresp has known interactions with medicines that inhibit specific liver enzymes (CYP3A4 or CYP1A2). These inhibitors can increase the amount of Daliresp in the body. Examples of such inhibitors listed in the drug's official interaction data include Erythromycin and Fluvoxamine.

Q: Does Daliresp work immediately, or does it take time to have an effect?

Daliresp is classified as a maintenance treatment intended to reduce the risk of future COPD flare-ups (exacerbations). Regulatory documents explicitly state that the medication is not indicated for the immediate relief of acute bronchospasm. As a maintenance therapy, its therapeutic benefit is generally realized over time rather than immediately.

Q: What is the incidence rate of significant weight decrease reported in clinical trials for Daliresp?

Data from two one-year clinical trials provides specific rates for weight change. According to this evidence, 20% of patients taking Daliresp experienced moderate weight loss (defined as 5%-10% of their body weight), and 7% experienced severe weight loss (more than 10% of their body weight). This was compared to lower rates for those receiving placebo.

Q: Are there any side effects of Daliresp that require immediate medical attention?

Official safety information advises that serious adverse reactions, notably suicidal ideation and behavior, as well as severe allergic reactions like Angioedema, warrant prompt medical consultation.

Q: Can back pain or flu-like symptoms be related to taking Daliresp?

Yes, official safety information lists both back pain and flu-like symptoms among the adverse reactions reported by patients. In clinical trials, these types of symptoms were classified as common adverse events.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Daliresp tablets.

Item	Official Regulatory Requirement
Storage Temperature	Store at 20 C to 25 C (68 F to 77 F) (Controlled Room Temperature), avoiding excess heat and moisture.
Container & Integrity	Must be kept in the original container, tightly closed, and protected from freezing.
Child Safety	The medication must be stored out of the sight and reach of children and pets, with safety caps secured.
Disposal Method	Unused or expired tablets should be disposed of via a local drug take-back program. If this is unavailable, mix the product with an undesirable substance (e.g., coffee grounds), seal it in a bag, and place it in the household trash.
Environmental Rule	Daliresp is not on the FDA's Flush List and must not be flushed down the toilet or poured down a drain.

These requirements ensure product stability (which supports a 3-year shelf life) and prevent unintentional exposure or environmental contamination.